INTRODUCTION
Myelodysplastic syndromes (MDS) are a diverse group of hematopoietic disorders [1] characterized by bone marrow failure, dysplasia of the cellular elements, and a risk of progression to acute myeloid leukemia (AML) [2, 3] . It affects about 3-4 individuals per 100,000 in the USA, with a higher prevalence (7-35 per 100,000 individuals) in the older (C60 years) population [4] . The incidence of MDS is low in Asian populations compared with Caucasian populations [5, 6] , with the median age of Asian patients approximately a decade younger than the Western population [7] . MDS can be either primary (de novo) or secondary (therapy related), with the incidence of secondary MDS occurring 3-8 years after exposure to prior chemotherapy or ionizing radiation [8] .
The management of MDS has always been a challenge to clinicians since the majority of the affected population consists of older patients with co-morbidities and who are generally intolerant to intensive chemotherapy.
Supportive or symptomatic care remains the preferred treatment option for many patients in this category. However, the magnitude of the survival improvement offered by this approach is inadequate [9] . The only curative option available is hematopoietic stem cell transplantation; however, a limited number of patients are suitable for this procedure due to older age, the lack of a histocompatible donor, or comorbid medical factors [10, 11] . With advances in research unraveling several mechanistic pathways and markers involved in the progression of the disease, a number of new treatment avenues for MDS are now being explored. A recent paradigm shift to hypomethylating agents such as azacitidine and decitabine, that are proving to alter the natural history of the disease, reduce disease-related symptoms, and improve patient quality of life, has changed the therapeutic landscape of this disease [10, 11] .
Decitabine
(5-aza-2 0 -deoxycytidine), a hypomethylating agent, is approved in the USA and several other countries (including China) for the treatment of previously treated or untreated, de novo or secondary MDS [12] .
Decitabine is efficacious in a broad range of hematologic disorders including MDS, AML, chronic myelomonocytic leukemia (CMML), and sickle cell anemia [13] [14] [15] [16] [17] [18] . A phase 3 study confirmed the superiority of decitabine versus supportive care in terms of the overall response rate (ORR; 17% vs. 0%, respectively) and a longer median time to AML or death (12.1 vs. 7.8 months, respectively) [19] . In pivotal studies conducted so far, the efficacy and safety of decitabine are well determined predominately in Western population, with Asians accounting for a very small percentage (approximately up to 7%) [19] [20] [21] [22] [23] . Multiple reports support the clinical and cytogenetic differences between Western and Asian patients with MDS that, to a large extent, might influence treatment outcomes, necessitating studies in an ethnicity-specific population [7, [24] [25] [26] [27] . Recent studies conducted in Korean and Japanese populations with MDS have confirmed the efficacy and feasibility of decitabine treatment in these populations [28, 29] . The current study was designed to evaluate the efficacy, safety, and pharmacokinetics (PK) of decitabine in Chinese patients with MDS using the approved treatment schedules (3-day and 5-day), in comparison with data from the rest of the world.
METHODS

Study Population
Enrolled patients (either sex, aged C18 years) 
Study Design
This open-label, phase 3b study was conducted minimum of 30 patients were assigned to the 3-day regimen, all remaining patients were assigned to 5-day regimen (Fig. 1) . A total of 24 patients were included for PK assessment in which six patients were from 3-day dosing schedule group and 18 patients were from the 5-day dosing group. Decitabine was available in the form of a sterile lyophilized powder that was reconstituted with sterile water for injection at the time of administration.
This study was conducted according to the Declaration of Helsinki, Good Clinical Practice guidelines, and other applicable regulatory a After reaching a minimum of 30 patients in the intent-to-treat analysis set for the 3-day treatment group, all remaining patients were enrolled into the 5-day treatment group. b All patients were treated for C4 cycles; treatment continued for a maximum of 2 years as long as patients continued to benefit. c Other reasons: primarily included patient voluntary withdrawal from the study, and withdraw from the study due to economic reasons or lack of efficacy. Decitabine for injection was supplied as a sterile lyophilized powder (50 mg decitabine), in a single dose vial to be aseptically reconstituted prior use. ITT intent to treat, IV intravenous, PK pharmacokinetics requirements. The protocol was reviewed and approved by an Independent Ethics Committee at each study site and informed consent was obtained from each patient before enrollment.
This trial is registered with ClinicalTrials.gov identifier, NCT01751867.
Assessments
Efficacy Evaluations
The primary efficacy endpoint was ORR, defined as complete response (CR) [30] 
RESULTS
Patient Disposition and Baseline Characteristics
Out of 135 patients enrolled in the study, 132
patients received decitabine treatment (3-day regimen, n = 34; 5-day regimen, n = 98) 
Extent of Exposure
A total of 132 patients received at least 1 dose of decitabine. Overall, the median number of treatment cycles was 3 in the 3-day treatment group and 4 in 5-day treatment group. The median number of decitabine infusions was 27 (range 9-153) for the 3-day treatment group and 20 (range 4-115) for the 5-day treatment group.
Concomitant Therapy
The most common concomitant medications received by patients at least once during the entire study included granulocyte-colony Table 4 ). The maximum AML-free survival time was 39.8? months in 3-day regimen and 43.4? months in 5-day regimen, but both were censored observations (it was not known whether patients had died or progressed to A patient was considered to be transfusion independent, if transfusion of red blood cells or platelets was not required for an eight-week period before the first dose of decitabine and during the study. For all patients, the transfusion independence rate at baseline was 33.3%, which increased to 49.6% during the treatment phase. In both treatment groups, the number of transfusion-independent patients increased during the decitabine treatment phase versus baseline (3-day regimen, 52.9% vs. 20.6%, respectively; 5-day regimen, 48.5% vs.
37.8%, respectively). Of the 88 transfusion-dependent patients at baseline, 50 remained transfusion dependent while the remaining 38 patients were transfusion independent by the end of treatment. Of the 44 transfusion-independent patients at baseline, 27 patients continued to be transfusion independent and 16 patients became transfusion dependent at the end of treatment (Table 5) .
Pharmacokinetics
The mean (standard deviation) plasma concentration-time profiles for both treatment groups are shown in Figs. 6 and 7. In the 5-day treatment group, the mean observed maximum plasma concentration (C max ) and area under curve (AUC) values on last day of the treatment (day 5) were markedly higher than in 3-day treatment group; the mean time when C max was observed (T max ) was lower in 5-day treatment group than in 3-day treatment group (Table 6) . Plasma decitabine concentrations were measurable up to 6 h post-dose in patients treated with the 3-day regimen and up to 4 h (the last sample time) in those from the 5-day regimen. Fig. 2 Time to the first and best response-combining both treatment groups (ITT analysis set). Only patients with remission were included in the analysis. CR complete remission, HI hematologic improvement, ITT intent to treat, mCR marrow complete remission, PR partial remission
Safety
The most common (C40%) AE was a decrease in white blood cell (WBC) count (67.4%), followed Myelodysplastic syndromes constitute varied disease conditions ranging from more indolent forms to those with a rapid evolution of AML [2, 3, 37] . From the clinical perspective, delaying the time to AML or death is a prime objective [20] , the DIVA trial (17.7 months) [27] , and another trial from Latin America (16 months) [37] . The subgroup analysis showed that the median survival time of high risk group was 10.8 months, which was similar to other research [19] . However, the Percentages in 'Total' column were calculated with the number of ITT patients treated as denominator; percentages of subgroup were calculated with the number of patients per baseline subgroup as denominator ITT analysis set included all patients who received at least 1 dose of decitabine ITT intent to treat, NA not applicable (patients who were treated less than 8 weeks and had no blood transfusion records were reported)
outcome was significantly better than other populations (30.7 and 24.3 months, respectively) [20, 37] . The reason may be due to the lower rate of abnormal chromosomes in these two subgroups (39% and 55%, respectively) compared with the high risk All observed toxicities were to be graded according to the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE), version 3.0, 2008 [41] Safety analysis set included all patients who received at least 1 dose of decitabine group (75%). According to the cytogenetic prognosis grading, the proportion of poor prognosis for chromosome in the two subgroups was 6% and 38%, respectively, which was much lower than 50% in the high risk group. Meanwhile, the proportion of concomitant disease in the two subgroup patients was also lower (47.4% and 62.1%, respectively) than the high risk group (75%) which may partly be responsible for the outcome.
One-year OS rate (68.4%) observed in this study was almost similar to that in the USA (66%) and Korean populations (74.8%) [28] .
Further, two-year survival rate of this trial (48.9%) was superior to South American (37%) [37] and Korean studies (42.2%) [38] .
Collectively, these studies suggest efficacious benefits of decitabine treatment in Asian [29] . Moreover, the percentage of patients who had received prior active MDS therapy was up to 48%, especially the chemotherapy account for 16%, which exceeds that of other reports [18, 20, 37] .
Importantly, the baseline clinical characteristics of patients in the current study indicate that they may have been in a worse disease status than other populations; this may, therefore, partly result in the observed CR differences when compared to the other trials.
Hypomethylation of DNA is associated with an alteration in hematological status that predicts the clinical response to treatment [39] . In this study, approximately 38.2% of patients showed a HI after the first dose of decitabine, which lasted until the end of treatment and which, in comparison with the Korean population, was slightly low (47.5%) [28] . In patients who were responders as evaluated by clinical efficacy assessment and in patients with CR as best response, the CRR, indicating the potential to alter the natural history of the disease, was marginally higher in Chinese patients (66.7%) compared to that in the ADOPT study in Caucasian patients (52%) [21] . Of note in this study, 69% of patients achieved clinical response at the end of second cycle and approximately 44% of patients achieved the best response in the first 2 cycles.
Patients with MDS eventually depend on chronic transfusions, which provide hematological stability; however, transfusion-related morbidities due to iron overload are of significant medical concern [40] .
Thus, reducing the transfusion dependency in patients would add to the treatment benefits. The transfusion independence rate improved significantly compared to baseline during treatment with decitabine.
No unexpected safety findings were observed in this Chinese population. The primary AEs noted were those of myelosuppression and complications resulting from cytopenias. The incidence of grade 3 or higher cytopenias during treatment as well as infectious complications appears similar to those seen with the approved decitabine regimen. Overall, incidences of deaths and serious AEs were low. AEs leading to discontinuation were slightly higher in the 3-day dosing schedule compared with the 5-day dosing regimen, which possibly correlates with the extent of study drug exposure. Overall, the safety outcomes indicated that decitabine has a manageable toxicity profile in elderly Chinese patients. Of note, all patients enrolled in the study had de novo MDS and the majority had an ECOG score of 0 or 1 so generalizability of these results to a wider population warrants caution.
CONCLUSIONS
Decitabine, at the doses studied, was efficacious for the treatment of MDS in Chinese patients.
The safety and PK profiles of decitabine were generally consistent with previous global studies in MDS, which were conducted primarily in Western populations. 
